Philip Morris International (PMI) has submitted premarket tobacco product applications (PMTAs) and modified risk tobacco product applications (MRTPAs) to the US Food and Drug Administration (FDA) for its Iqos Iluma heated tobacco products (HTPs).
As previously announced during the presentation of its financial results last week, the company was expected to file the applications by the end of October.
They are strong applications backed by international evidence of how Iqos Iluma products can lead more adults to stop smoking, said Stacey Kennedy, president of Americas Region and CEO of PMI US. She urged the FDA to prioritise them for review.
Antonia is a member of the editorial team and holds a masters degree in Law from the University of Naples Federico II, Italy. She moved in 2013 to London, where she completed a postgraduate course at the London School of Journalism. In the UK, she worked as a news reporter for a financial newswire and a magazine before moving to Barcelona in 2019.
Our Key Benefits
The global novel nicotine market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.
TobaccoIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.
Stay informed of any legal and market change in the sector that impacts your organisation
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organisation
Thanks for getting in touch with us
Please leave your enquiry and we will get back to you within 24 hours
Start your FREE trial
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis.
LATEST ALERTS
